Prostate Cancer - Results from #420

Implementation of fracture risk assessment in men with prostate cancer requiring long-term androgen deprivation therapy: a systematic scoping review using the i-PARIHS implementation framework. August 14, 2024

A Detailed Clinical Case of Localized Prostate Tumors Treated with Nanoparticle-Assisted Sub-Ablative Laser Ablation. August 13, 2024

Delayed definitive management of localized prostate cancer: what do we know? August 13, 2024

The survival outcomes of localized low-risk prostate cancer, a population-based study using NCDB. August 13, 2024

Stereotactic Body Radiation Adoption Impacts Prostate Cancer Treatment Patterns. August 13, 2024

Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patients. August 13, 2024

Intratumoral vitamin D signaling and lethal prostate cancer. August 12, 2024

Systemic Treatments for Metastatic Prostate Cancer in 2024. August 12, 2024

The Sensitivity and Specificity of Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Predicting Seminal Vesicle Invasion in Clinically Significant Prostate Cancer: A Mult August 12, 2024

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. August 12, 2024

Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer. August 12, 2024

Controversies in prostate cancer screening. August 12, 2024

Impact of definitive radiotherapy on metabolic response measured with 68Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer. August 9, 2024

External Validation of Stockholm3 in a Retrospective German Clinical Cohort. August 9, 2024

Outcomes after laser enucleation of the prostate with and without significant storage symptoms. August 9, 2024

Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. August 9, 2024

MYBL2 Drives Prostate Cancer Plasticity: Inhibiting its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer. August 9, 2024

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). August 9, 2024

Prevention of Device-Related Infections in Patients with Cancer: Current Practice and Future Horizons August 8, 2024

Centralized prostatectomy with intraoperative NeuroSAFE margin assessment improves surgical margin control. August 8, 2024

Page 22 of 1436